awmsg logo



everolimus (Certican®)


Reference No. 436

Publication date:
20/05/2015


Appraisal information

everolimus (Certican®) 1.0 mg tablet
everolimus (Certican®) 0.25 mg tablet
everolimus (Certican®) 0.50 mg tablet
everolimus (Certican®) 0.75 mg tablet


Company: Novartis Pharmaceuticals UK Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 15/05/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, everolimus (Certican®) cannot be endorsed for use within NHS Wales for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a cardiac transplant.
Statement of Advice (SOA)
Download